RolerRx and Abbott Join Forces In Psoriasis Treatment

TolerRx Inc. has entered into an agreement with Abbott for the manufacturing of TolerRx’s TRX4 monoclonal antibody to treat diabetes and severe psoriasis. TolerRx is a Cambridge-based biopharmaceutical company specializing in the discovery, development and commercialization of novel therapies to treat patients with immune-mediated diseases. Abbott is a global health-care corporation with laboratories in Worcester.TolerRx has two antibodies in clinical development: TRX4 in type 1 diabetes and psoriasis, and TRX1 in cutaneous lupus erythematosus. The company is enrolling subjects in a Phase 1b/2 trial of type 1 diabetes and a Phase 1b trial of moderate to severe psoriasis.Abbott will perform scale-up and GMP manufacturing of TRX4 for use in clinical trials, as well as supply commercial-grade material to support regulatory submissions and potential commercial launch.